Sarah Nemec bought $1,973 of BOLT
Senior VP, Finance and PAO at Bolt Biotherapeutics, Inc.. 509 shares at an average of $3.88, traded Jun 5, 2026, filed Sep 21, 2026.
Score components
- +15RoleOfficer
- 0Trade size$2k at market
- +6Relative to holdingsHoldings up 36%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-396892, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | POpen-market purchase Common Stock | +509 | $3.88 | $1,973 | 1,924 | 23 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock | -843 | $3.77 | $3,181 | 24,081 | 23 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock | -2,922 | $3.32 | $9,696 | 21,159 | 23 d ago |
| Sep 18, 2026 | SOpen-market sale Common Stock | -4,077 | $3.24 | $13k | 17,082 | 23 d ago |
Related signals
Other insiders at Bolt Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $2,469 637 shares | +28% | |
| 57Moderate | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $58k 17,566 shares | -41% | |
| 45Moderate | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $26k 7,842 shares | -31% | |
| 51Moderate | Bolt Biotherapeutics, Inc. | Grant Yonehiro Chief Operating Officer | $44k 13,176 shares | -43% | |
| 34Weak | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $576 125 shares | +10% | |
| 44Moderate | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $576 125 shares | +6% | |
| 44Moderate | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $687 125 shares | +6% | |
| 34Weak | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $687 125 shares | +15% | |
| 36Weak | Bolt Biotherapeutics, Inc. | William P. Quinn President, CEO and CFO | $2,835 5,000 shares | +14% | |
| 29Weak | Bolt Biotherapeutics, Inc. | Sarah Nemec Senior VP, Finance and PAO | $2,835 5,000 shares | +44% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.